Meta-analysis on the Influence of Testosterone Therapy on Male Kidney Function
DOI:
https://doi.org/10.35516/jmj.v60i2.3993Keywords:
Kidney Function Tests, Male, Meta-Analysis, Testosterone TherapyAbstract
Objective: Testosterone plays a significant role in kidney function. Both hypogonadism and hypergonadism, which can affect testosterone levels, have been associated with alterations in kidney function. This review provides a comprehensive and up-to-date overview of the potential impact of testosterone therapy on kidney function among male patients.
Method: We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Comprehensive search through Scopus, Embase, and Web of Science databases, with publications included up to June 11, 2023. Eligible studies included adult men aged 18 years and older who received testosterone therapy and reported kidney function outcomes, including randomized controlled trials (RCTs), and observational studies (prospective, retrospective, or case-control). Exclusion criteria included reviews, non-original articles, studies involving non-human subjects, duplicate reports, and studies with insufficient data. Statistical analysis was performed using a random-effects model, and variability was assessed using I². The review protocol was registered with PROSPERO (CRD42023456010).
Results: Out of 13 articles, encompassing 39,692 individuals in the treatment group and 10,375 in the control group from studies conducted in seven different countries. The meta-analysis revealed a noticeable difference in age (MD= -0.56; 95% CI: -0.68, -0.45; p<0.001). Testosterone levels were significantly lower in the control group (MD= -0.41; 95% CI: -0.52, -0.30; p<0.001). Baseline blood urea nitrogen concentration was significantly higher in the testosterone treatment group than in the control group, with this difference being statistically significant (MD= 1.66; 95% CI: 1.10, 2.23; p<0.001). Following treatment, blood urea nitrogen was lower in the testosterone treatment group than in the control group, though this difference was not statistically significant (MD= -0.44; 95% CI: -0.93, 0.05; p=0.079). The difference in uric acid levels between the treatment and control groups was not statistically significant (MD= 0.11; 95% CI: -0.02, 0.24; p=0.08). While these non-significant findings may not directly indicate a clinically meaningful impact, they still highlight potential trends that should be explored further, especially considering that BUN and uric acid levels are important markers of kidney function and could be influenced by testosterone therapy over the long term.
Conclusion: Testosterone therapy may influence kidney function, though further studies are needed to clarify its long-term effects and clinical significance.
References
1. Alwani M, Al-Zoubi RM, Al-Qudimat A, Yassin A, Aboumarzouk O, Al-Rumaihi K, et al. The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study. Ann Med Surg (Lond). 2021; 69: 102748.
2. Al-Zoubi RM, Al-Qudimat A, Al-Rumaihi K, Talib R, Mahdi M, Yassin A, et al. Pd20-11 Endocrine Outcomes of Long-Term Testosterone Treatment in Hypogonadal Men: 15 Years Data from a Prospective Controlled Registry Study. Journal of Urology. 2021; 206(Supplement 3).
3. van der Burgh AC, Khan SR, Neggers S, Hoorn EJ, Chaker L. The role of serum testosterone and dehydroepiandrosterone sulfate in kidney function and clinical outcomes in chronic kidney disease: a systematic review and meta-analysis. Endocr Connect. 2022; 11(6).
4. Yassin A, Haider KS, Talib RA, Aboumarzouk OM, Al-Zoubi RM, Al-Qudimat AR, et al. Anemia due to hypogonadism can be successfully treated in hypogonadal men with testosterone replacement: Real-World data from a controlled Registry Study. European Urology. 2022; 81.
5. Aboumarzouk OM, Aksam Y, Al-Zoubi RM, Alwani MM, Al-Qudimat AR, Rejeb MA, et al. Improvement of erectile function, weight loss and reduced inflammation under long-term treatment with testosterone treatment in hypogonadal men for up to 12 years. European Urology. 2022; 81.
6. Al-Qudimat AR, Al Darwish MB, Altahtamouni SB, Singh K, Al-Zoubi RM, Aboumarzouk OM, et al. Chronic kidney diseases and the risk of colorectal cancer: A systematic review and meta-analysis. Arab Journal of Urology. 2023; 21(4): 258-66.
7. Al-Zoubi RM, Alwani M, Aboumarzouk OM, Elaarag M, Al-Qudimat AR, Ojha L, et al. Updates on androgen replacement therapy and lower urinary tract symptoms: a narrative review. Aging Male. 2022; 25(1): 234-41.
8. Al-Zoubi RM, Yassin AA, Alwani M, Al-Qudimat A, Aboumarzouk OM, Zarour A, et al. A systematic review on the latest developments in testosterone therapy: Innovations, advances, and paradigm shifts. Arab J Urol. 2021; 19(3): 370-5.
9. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018; 14(3): 151-64.
10. Filler G, Ramsaroop A, Stein R, Grant C, Marants R, So A, et al. Is Testosterone Detrimental to Renal Function? Kidney Int Rep. 2016; 1(4): 306-10.
11. Silbiger SR. Raging hormones: gender and renal disease. Kidney Int. 2011; 79(4): 382-4.
12. Yassin A, Bassam A, Talib T, Moulhem M. Long-Term Testosterone Treatment Improves Fatty Liver and Kidney Function with Safe Outcomes on Cardio-, Metabolic and Prostate Health in Men with Hypogonadism. Prospective Controlled Studies. Current trends in Internal Medicine. 2022; 6(3).
13. Al-Qudimat A, Al-Zoubi RM, Yassin AA, Alwani M, Aboumarzouk OM, AlRumaihi K, et al. Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study. Arab J Urol. 2021; 19(3): 376-86.
14. Al-Qudimat A, Alwani M, Al-Zoubi RM, Al-Rumaihi K, Talib R, Haider K, et al. MP58-12 Less mortality and less major adverse cardiovascular events (mace) under long-term testosterone therapy (tth): 15-year data from a prospective controlled registry study. Journal of Urology. 2021; 206(Supplement 3).
15. Alwani M, Yassin A, Talib R, Al-Qudimat A, Aboumarzouk O, Al-Zoubi RM, et al. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data. Vasc Health Risk Manag. 2021; 17: 497-508.
16. Masuda H. Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy. Anticancer Res. 2023; 43(1): 305-9.
17. Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, Toma H. The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol. 2001; 166(3): 1078-82.
18. Zhang X, Huang K, Saad F, Haider KS, Haider A, Xu X. Testosterone Therapy Reduces Cardiovascular Risk Among Hypogonadal Men: A Prospective Cohort Study in Germany. Androgens: Clinical Research and Therapeutics. 2021; 2(1): 64-72.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5): 336-41.
20. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews. 2016; 5(1): 210.
21. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019; 366: l4898.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-60.
23. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006; 295(6): 676-80.
24. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama. 2008; 299(1): 39-52.
25. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997; 82(11): 3793-6.
26. Hendler ED, Goffinet JA, Ross S, Longnecker RE, Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med. 1974; 291(20): 1046-51.
27. Morley JE, Perry HM, 3rd, Kaiser FE, Kraenzle D, Jensen J, Houston K, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc. 1993; 41(2): 149-52.
28. Skiba R, Rymarz A, Matyjek A, Dymus J, Woźniak-Kosek A, Syryło T, et al. Testosterone Replacement Therapy in Chronic Kidney Disease Patients. Nutrients. 2022; 14(16).
29. Yeo JK, Koo HS, Yu J, Park MG. Effects of Testosterone Treatment on Quality of Life in Patients With Chronic Kidney Disease. Am J Mens Health. 2020; 14(3): 1557988320917258.
30. Rishi S, Olurinde O, Peter W, Mukut S, Mariana G-T, Archana G, et al. Testosterone Replacement Therapy (TRT) is Associated with Delayed Progression of Chronic Kidney Disease: A Retrospective Analysis of Testosterone Normalization in US Veterans. Annals of Nephrology. 2020; 5(1).
31. Amory JK, Kalhorn TF, Page ST. Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception. J Androl. 2008; 29(3): 260-71.
32. Firas A, Areej A. Z, A. S, Hameid A. R. Effect of Nutritional Supplementation and Anabolic Androgenwith Testosterone on Kidney and Liver Function of Athletes inBaghdad City. Journal of Global Pharma Technology. 2018; 0975(0975-8542).
33. Sahlin KB, Pla I, Sanchez A, Pawłowski K, Leijonhufvud I, Appelqvist R, et al. Short-term effect of pharmacologically induced alterations in testosterone levels on common blood biomarkers in a controlled healthy human model. Scand J Clin Lab Invest. 2020; 80(1): 25-31.
34. Aksam Y, Almehmadi Y, Alwani M, Mahdi M, Jager A, Talib R, et al. Long-term Testosterone Therapy Improves Renal Function in Men with Hypogonadism: A Real-life Prospective Controlled Registry. Clinical Nephrology and Research. 2020; 7(1): 1095.
35. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab. 1999; 84(5): 1527-33.
36. Lam T, Poljak A, McLean M, Bahl N, Ho KKY, Birzniece V. Testosterone prevents protein loss via the hepatic urea cycle in human. Eur J Endocrinol. 2017; 176(4): 489-96.
37. Pacobahyba N, Vale RGdS, Souza SLPd, Simão R, Santos E, Dantas EHM. Força muscular, níveis séricos de testosterona e de ureia em jogadores de futebol submetidos à periodização ondulatória. Revista Brasileira de Medicina do Esporte. 2012; 18(2): 130-3.
38. Giri M, He L, Hu T, Puri A, Zheng X, Dai H, et al. Blood Urea Nitrogen Is Associated with In-Hospital Mortality in Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Propensity Score Matching Analysis. J Clin Med. 2022; 11(22).
39. Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, Hispanic, and older patients with chronic renal failure. Am J Kidney Dis. 1999; 33(4): 728-33.
40. Yang Y. Application of serum CK and BUN determination in monitoring pre-competition training of badminton athletes. J Huazhong Univ Sci Technolog Med Sci. 2007; 27(1): 114-6.
41. Zheng C. Analysis and Research on Fitness Biomarkers in Volleyball Athletes during Competition. Revista Brasileira de Medicina do Esporte. 2023; 29.
42. Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020; 8(6): 1598-605.
43. Li Z, Yang P, Xue S, Yuan S, Yuan L, Yan R, et al. Testosterone promotion effect of Eucommia ulmoides staminate flower via the steroidogenic pathway and potential hormonal mechanism. Sci Rep. 2022; 12(1): 18765.
44. Chen JJ, Lukyanenko Y, Hutson JC. 25-hydroxycholesterol is produced by testicular macrophages during the early postnatal period and influences differentiation of Leydig cells in vitro. Biol Reprod. 2002; 66(5): 1336-41.
45. Li L, Ju H, Jin H, Chen H, Sun M, Zhou Z. Low Testosterone Level and Risk of Adverse Clinical Events among Male Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Cohort Studies. J Healthc Eng. 2022; 2022: 3630429.
46. Gyawali P, Martin SA, Heilbronn LK, Vincent AD, Taylor AW, Adams RJT, et al. The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men. Acta Diabetol. 2018; 55(8): 861-72.
47. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004; 27(5): 1036-41.
48. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000; 23(4): 490-4.
49. Jeppesen LL, Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS, Winther K. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol. 1996; 16(6): 749-54.
50. Yeap BB, Hyde Z, Almeida OP, Norman PE, Chubb SA, Jamrozik K, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009; 94(7): 2353-9.
51. Akishita M, Fukai S, Hashimoto M, Kameyama Y, Nomura K, Nakamura T, et al. Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res. 2010; 33(6): 587-91.
52. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006; 91(3): 843-50.
53. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002; 87(8): 3632-9.
54. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999; 107(2): 123-36.
55. Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr. 2004; 80(2): 496-503.
56. Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013; 369(10): 932-43.
57. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005; 352(20): 2049-60.
58. Carrero JJ, Barany P, Yilmaz MI, Qureshi AR, Sonmez A, Heimburger O, et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant. 2012; 27(2): 709-15.
59. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med. 2006; 166(13): 1380-8.
60. Kurita N, Horie S, Yamazaki S, Otani K, Sekiguchi M, Onishi Y, et al. Low Testosterone Levels and Reduced Kidney Function in Japanese Adult Men: The Locomotive Syndrome and Health Outcome in Aizu Cohort Study. J Am Med Dir Assoc. 2016; 17(4): 371 e1-6.
61. Paller CJ, Shiels MS, Rohrmann S, Menke A, Rifai N, Nelson WG, et al. Association between sex steroid hormones and hematocrit in a nationally representative sample of men. J Androl. 2012; 33(6): 1332-41.
62. Edey MM. Male Sexual Dysfunction and Chronic Kidney Disease. Front Med (Lausanne). 2017; 4: 32.
63. Thirumavalavan N, Wilken NA, Ramasamy R. Hypogonadism and renal failure: An update. Indian J Urol. 2015; 31(2): 89-93.
64. Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Advances in Chronic Kidney Disease. 2004; 11(4): 337-41.
65. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013; 9(7): 414-24.
66. Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014; 15(9): 1247-64.
67. Jenkins CR, Rittel A, Sturdivant RX, Wan J, Clerc PG, Manning E, et al. Glycemic benefits with adherence to testosterone therapy in men with hypogonadism and type 2 diabetes mellitus. Andrology. 2021; 9(4): 1076-85.
68. Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem. 2004; 279(50): 52282-92.
69. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011; 8(11): 3204-13.
70. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018; 103(5): 1715-44.
71. Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014; 11(6): 1577-92.
72. Elliott J, Kelly SE, Millar AC, Peterson J, Chen L, Johnston A, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017; 7(11): e015284.
73. Wang C, Swerdloff RS. Testosterone Replacement Therapy in Hypogonadal Men. Endocrinol Metab Clin North Am. 2022; 51(1): 77-98.
74. DelConte A, Papangkorn K, Kim K, Bruno BJ, Chidambaram N, Khera M, et al. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022; 10(4): 669-76.
75. Pencina KM, Travison TG, Cunningham GR, Lincoff AM, Nissen SE, Khera M, et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024; 109(2): 569-80.
76. Rizk PJ, Kohn TP, Pastuszak AW, Khera M. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017; 27(6): 511-5.
77. Fugh-Berman A, Scialli AR. Testosterone and sexual function. Curr Opin Urol. 2017; 27(6): 516-8.
78. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause. 2003; 10(5): 390-8.
79. Bryant C, Hoppe BS, Mendenhall NP, Henderson RH, Nichols RC, Morris CG, et al. Testosterone replacement therapy in men with prostate cancer after proton therapy. Journal of Clinical Oncology. 2014; 32(4_suppl): 208-.
80. Krysiak R, Gilowski W, Okopien B. The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism. Pharmacol Rep. 2016; 68(1): 196-200.
81. Ullah MI, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014; 8: 101-12.
82. Jhawar N, Chirila R. A review of testosterone supplementation and cardiovascular risk. Rom J Intern Med. 2023; 61(1): 35-40.
83. Adams MR, Pijut KD, Uttal-Veroff KC, Davis GA. Acute Portal and Superior Mesenteric Vein Thrombosis with Topical Testosterone Therapy: An Adverse Drug Event Case Report. J Pharm Pract. 2023; 36(4): 988-92.
84. Martinez C, Suissa S, Rietbrock S, Katholing A, Freedman B, Cohen AT, et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016; 355: i5968.
